Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Snape MD, et al. Among authors: anemona a. JAMA. 2008 Jan 9;299(2):173-84. doi: 10.1001/jama.2007.29-c. JAMA. 2008. PMID: 18182599 Clinical Trial.
MAIN OUTCOME MEASURE: Percentage of infants with a human complement serum bactericidal activity (hSBA) titer >or=1:4 after a primary course of MenACWY and after a 12-month booster. ...With a post hoc intention-to-treat analysis with imputed values f …
MAIN OUTCOME MEASURE: Percentage of infants with a human complement serum bactericidal activity (hSBA) titer >or=1:4 after a
Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults.
Gasparini R, Conversano M, Bona G, Gabutti G, Anemona A, Dull PM, Ceddia F. Gasparini R, et al. Among authors: anemona a. Clin Vaccine Immunol. 2010 Apr;17(4):537-44. doi: 10.1128/CVI.00436-09. Epub 2010 Feb 17. Clin Vaccine Immunol. 2010. PMID: 20164251 Free PMC article. Clinical Trial.
Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Perrett KP, et al. Among authors: anemona a. Pediatr Infect Dis J. 2009 Mar;28(3):186-93. doi: 10.1097/INF.0b013e31818e037d. Pediatr Infect Dis J. 2009. PMID: 19209097 Clinical Trial.
A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.
Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. Jackson LA, et al. Among authors: anemona a. Pediatr Infect Dis J. 2009 Feb;28(2):86-91. doi: 10.1097/INF.0b013e31818a0237. Pediatr Infect Dis J. 2009. PMID: 19116603 Clinical Trial.
This study compared the tolerability and immunogenicity in adolescents of a candidate quadrivalent meningococcal CRM197 glycoconjugate vaccine against serogroups A, C, W-135, and Y (MenACWY-CRM) with that of the licensed unconjugated quadrivalent polysaccharide vacc …
This study compared the tolerability and immunogenicity in adolescents of a candidate quadrivalent meningococcal CRM197 glycoconjugat …
Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine.
Kanra G, Viviani S, Yurdakök K, Ozmert E, Anemona A, Yalçin S, Demiralp O, Bilgili N, Kara A, Cengiz AB, Mutlu B, Baldini A, Marchetti E, Podda A. Kanra G, et al. Among authors: anemona a. Pediatr Int. 2003 Jun;45(3):314-8. doi: 10.1046/j.1442-200x.2003.01706.x. Pediatr Int. 2003. PMID: 12828588 Clinical Trial.
A total of 520 healthy infants were randomized in a 2:2:1 ratio to receive at either Chiron Hib/AlPO4 vaccine or VaxemHib (aluminum hydroxide adjuvant) vaccine or HibTiter (no adjuvant). ...After each vaccination parents filled out a diary for 7 days. RESULTS
A total of 520 healthy infants were randomized in a 2:2:1 ratio to receive at either Chiron Hib/AlPO4 vaccine or VaxemHib (alu
Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents.
Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Gill CJ, et al. Among authors: anemona a. Hum Vaccin. 2010 Nov;6(11):881-7. doi: 10.4161/hv.6.11.12849. Epub 2010 Nov 1. Hum Vaccin. 2010. PMID: 21339701 Free PMC article.
Safety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adults.
van Damme P, Kafeja F, Anemona A, Basile V, Hilbert AK, De Coster I, Rondini S, Micoli F, Qasim Khan RM, Marchetti E, Di Cioccio V, Saul A, Martin LB, Podda A. van Damme P, et al. Among authors: anemona a. PLoS One. 2011;6(9):e25398. doi: 10.1371/journal.pone.0025398. Epub 2011 Sep 30. PLoS One. 2011. PMID: 21980445 Free PMC article. Clinical Trial.
Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.
Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F. Halperin SA, et al. Among authors: anemona a. Eur J Clin Microbiol Infect Dis. 2010 Mar;29(3):259-67. doi: 10.1007/s10096-009-0848-8. Epub 2009 Dec 22. Eur J Clin Microbiol Infect Dis. 2010. PMID: 20033465 Clinical Trial.
Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines.
Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, Grunwald U, Bedell L, Anemona A, Dull PM. Arguedas A, et al. Among authors: anemona a. Vaccine. 2010 Apr 19;28(18):3171-9. doi: 10.1016/j.vaccine.2010.02.045. Epub 2010 Feb 26. Vaccine. 2010. PMID: 20189491 Clinical Trial.
Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials.
Bhutta ZA, Capeding MR, Bavdekar A, Marchetti E, Ariff S, Soofi SB, Anemona A, Habib MA, Alberto E, Juvekar S, Khan RM, Marhaba R, Ali N, Malubay N, Kawade A, Saul A, Martin LB, Podda A. Bhutta ZA, et al. Among authors: anemona a. Lancet Infect Dis. 2014 Feb;14(2):119-29. doi: 10.1016/S1473-3099(13)70241-X. Epub 2013 Nov 28. Lancet Infect Dis. 2014. PMID: 24290843 Clinical Trial.
35 results
Jump to page
Feedback